Cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau, and quantification of cortical amyloid burden by positron emission tomography (PET) remain among the best‐established biomarkers of Alzheimer's disease (AD). This evidence concerns the gene MAPT and Alzheimer disease.